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Ischemic stroke subtypes and migraine
with visual aura in the ARIC study
ABSTRACT
Objective: To investigate the association amongmigraine, ischemic stroke, and stroke subtypes in
the Atherosclerosis Risk in Communities (ARIC) study.
Methods: In this ongoing, prospective, longitudinal community-based cohort study, participants
were given an interview ascertaining migraine history in 1993–1995, and were followed for all
vascular events, including stroke. All stroke events over the subsequent 20 years were adjudi-
cated and classified into stroke subtypes by standard definitions. Cox proportional hazards mod-
els adjusted for stroke risk factors were used to study the relationship between migraine and
ischemic stroke, overall, as well as stroke subtypes (cardioembolic, lacunar, or thrombotic).
Results: We identified 1,622 migraineurs among 12,758 participants. Mean age of the study
population at the 3rd clinical visit was 59 years. When compared to nonheadache participants,
there was a significant association betweenmigraine with visual aura and ischemic stroke (hazard
ratio [HR] 1.7, 95% confidence interval [CI] 1.2–2.6, p 5 0.008). Migraine without visual aura
was not significantly associated with ischemic stroke (HR 1.2, CI 1.0–1.8, p 5 0.28) when
compared to nonheadache participants. Among the 3 subtypes of ischemic stroke evaluated,
migraine with visual aura was significantly associated only with cardioembolic stroke (HR 3.7,
95% CI 1.6–8.7, p 5 0.003).
Conclusion: In participants with migraine with visual aura in late middle age, increased risk of car-
dioembolic stroke was observed. Migraine with visual aura was linked to increased stroke risk,
while migraine without visual aura was not, over the period of 20 years. These results are specific
to older migraineurs. Neurology® 2016;87:2527–2532
GLOSSARY
ARIC 5 Atherosclerosis Risk in Communities; BMI 5 body mass index; CGRP 5 calcitonin gene-related peptide; CI 5
confidence interval; HR 5 hazard ratio; ICHD 5 International Classification of Headache Disorders; LDL 5 low-density
lipoprotein; NSAID 5 nonsteroidal anti-inflammatory drugs; PFO 5 patent foramen ovale; WHS 5 Women’s Health Study.
Epidemiologic studies have demonstrated that migraine with aura is associated with increased
risk of ischemic stroke.1–6 A recent review on migraine and stroke presented substantial neuro-
imaging and genetic evidence supporting the link between migraine with aura and ischemic
stroke.7 Furthermore, subclinical infarcts have been linked to migraine.8,9 However, there is
a paucity of data on the pathogenesis of increased risk of ischemic stroke in migraine with aura.
Investigation of stroke subtypes and association with migraine may shed light on the potential
mechanism. Furthermore, there are still controversial reports on relationship between migraine
without aura and ischemic stroke; this may be due to variations in study populations across prior
published studies.10–14 In the Atherosclerosis Risk in Communities (ARIC) study, we proposed
to evaluate the association between migraine with and without aura and ischemic stroke and to
expand on prior work in ARIC and in other studies. While other studies have examined the
relationship between migraine and stroke, we specifically aimed to examine the association
between ischemic stroke subtypes, including thrombotic, cardioembolic, and lacunar strokes,
and migraine with and without aura.
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METHODS Study population. The cohort of the ARIC
study was initiated in 1987 with an aim of studying the causes
of atherosclerosis and clinical sequelae.15 The study enrolled
15,792 participants within the age group of 45–64 years in 4
different US communities (Forsyth County, North Carolina;
Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and
Washington County, Maryland). Baseline information was col-
lected at the first visit from 1987 to 1989, and follow-up visits
every 3 years for visits 2 (1990–1992), 3 (1993–1995), and 4
(1996–1998) were completed. Surviving participants completed
visit 5 during 2011–2013. Vascular risk factors and markers as
well as various health interviews were completed at each visit, and
participants underwent laboratory testing at each visit.15 In
addition, participants are contacted annually by telephone, and
queried about any hospitalizations. Hospital medical records are
obtained for all vascular hospitalizations, including stroke.
In the current study, we included all participants who com-
pleted the third clinic visit (1993–1995) in ARIC (n 5 12,882).
We excluded participants with first ischemic stroke event that
occurred before the third clinical visit in the ARIC study (1993–
1995) (n 5 87) and participants with missing headache informa-
tion (n 5 37). A total of 12,758 participants fulfilled our criteria
and were included for analysis. For analysis, only individuals with-
out any headache history were included as controls.
Standard protocol approvals, registrations, and patient
consents. The institutional review boards of all participating in-
stitutions approved the study, and all participants provided writ-
ten informed consent.
Assessment of migraine. A headache questionnaire was admin-
istered to all participants who attended ARIC visit 3. Based on
results from this questionnaire, modified International Classifica-
tion of Headache Disorders (ICHD III beta)16 diagnostic criteria
were used to characterize migraine with visual aura and migraine
without visual aura. Participants were classified as having
migraine if they endorsed headaches lasting at least 4 hours or
longer in duration, with throbbing or pulsating pain, and if head-
aches were mostly on one side; headaches must have also been
accompanied by photophobia and phonophobia or nausea or
vomiting. This information was all identified from the headache
questionnaire used in visit 3. In addition, headache was separated
into migraine with visual aura if the participant reported seeing
spots, jagged lines, or heat waves in one or both eyes before onset
of headache. All other migraine headaches that did not qualify for
migraine with visual aura were classified as migraine without
visual aura. All other headaches that lasted for more than 4 hours
and did not qualify for migraine headache were classified as non-
migraine headaches and those individuals who did not report
a history of headaches greater than 4 hours were classified into
the no headache group. Individuals with nonmigraine headaches
were excluded from analysis.
Adjudication of stroke subtypes. Neuroimaging (CT or
MRI) was mandatory for stroke diagnosis and exclusion of non-
stroke reasons for neurologic symptoms, although images were
not reviewed directly (rather, reports were reviewed). Stroke diag-
nosis was based on computer-derived diagnosis and physician
medical record review, with differences adjudicated by a second
physician reviewer. Verified incident ischemic strokes included
all the events occurring between the date of the third clinic
visit (1993–1995) and December 2012. Classification required
evidence of sudden or rapid onset of neurologic symptoms lasting
.24 hours or leading to death, in the absence of evidence for
a nonstroke cause. Ischemic strokes were further classified
according to pathogenic subtype as thrombotic brain infarction,
lacunar infarction, or cardioembolic stroke, according to criteria
adopted from the National Survey of Stroke subtype
classification.17,18 Neuroimaging patterns of infarct distribution
were not considered per the algorithm based on the National
Survey of Stroke available at the time of this study initiation.
Statistical analysis. We considered baseline demographics
including age, sex, and race for the analysis and investigated addi-
tional covariates including hypertension, diabetes, current smok-
ing status, regular use of nonsteroidal anti-inflammatory drugs
(NSAID), physical activity, serum low-density lipoprotein
(LDL), and body mass index (BMI). Low physical activity is
considered significant if performed for less than 3 h/wk for at
least a month. Cox proportional hazards models were used to
analyze the association among migraine with visual aura,
migraine without visual aura, and incidence of ischemic stroke.
We used survival analysis to evaluate the incidence of each
subtype of ischemic stroke in migraine with visual aura when
compared to migraine without visual aura. All data analysis was
carried out using SAS version 9.4 (SAS institute Inc., Cary, NC).
RESULTS The mean age of the study participants was
59 years (range 49–73 years) at the time of start of
prospective follow-up (visit 3); among included
participants, 77% were white and 56% were women.
Among study participants at the third clinical visit,
12.6% had a history of migraine headaches, with
3.6% having migraine with visual aura and 9% with
migraine without visual aura. The average duration of
migraine history in this subset of population was 19
years. Demographics and stroke risk factors of the
included 12,758 participants are presented in table 1.
Migraine was more prevalent among women when
compared to men (3:1). Stroke risk factors including
hypertension, diabetes, and obesity were slightly more
prevalent in migraine with visual aura when compared
to the rest of the population.
In this cohort, 6% of the total population had
a first-time ischemic stroke since the third clinic visit;
during the same period, 5.3% of all migraineurs (with
or without visual aura) developed ischemic stroke. Fur-
thermore, the incidence rate of stroke in migraine with
visual aura was 4.1 per 1,000 persons per year, and was
2.07 per 1,000 persons per year in migraine without
visual aura. Table 2 summarizes the incidence rate of
ischemic stroke stratified by migraine/headache type.
The unadjusted association between migraine with
visual aura and ischemic stroke as compared to the risk
of ischemic stroke among those without any headache
did not reach statistical significance (hazard ratio [HR]
1.4, confidence interval [CI] 1.0–2.0, p5 0.052). After
adjustment for covariates, the association between
migraine with visual aura and ischemic stroke was sig-
nificant (HR 1.67, CI 1.1–2.4, p 5 0.014). We
observed an association betweenmigraine without visual
aura and ischemic stroke when compared to the general
population in ARIC without any history of headache
(HR 1.47, CI 1.0–2.0, p5 0.01); however, after adjust-
ing for age, sex, race/center, hypertension, diabetes,
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current smoking status, regular use of NSAID, physical
activity, serum LDL, and BMI, the association was not
statistically significant (HR 1.2, CI 0.87–1.75, p 5
0.28). These results are summarized in table 3.
Among the 3 stroke subtypes, there was an
increased hazard of cardioembolic stroke in partici-
pants with migraine with visual aura when compared
to migraine without visual aura (HR 3.7, 95% CI
1.6–8.7, p 5 0.003), but not of lacunar (HR 2.6,
95% CI 0.9–7.4, p 5 0.07) or nonlacunar throm-
botic stroke (HR 1.6, 95% CI 0.9–2.8, p 5 0.09).
The association of thrombotic, cardioembolic, or
lacunar subtype of stroke and migraine with or with-
out visual aura is demonstrated in Kaplan-Meier sur-
vival graphs (figure).
DISCUSSION We investigated the association
between various stroke subtypes in a large prospective
cohort, which has rarely been reported on historically.
An earlier study in ARIC11 suggested that migraine
with visual aura was associated with an increased occur-
rence of stroke/TIA, and since that time, an additional
546 new adjudicated ischemic stroke events were iden-
tified in the subsequent 12-year period (2001–2012).
This allowed us to study temporal relationship of
migraine with and without visual aura and ischemic
stroke, and stroke subtypes over 2 decades (1993–
2012). This study demonstrated a significant
increased risk of cardioembolic stroke in older
migraineurs with visual aura as compared to
participants with migraine without visual aura,
suggesting that clinicians might consider initiation of
workup for assessment of factors predisposing to
cardioembolism in migraine with visual aura patients,
especially among those who have other coexisting
stroke risk factors. It is possible that an increased risk
of cardioembolic stroke is secondary to undiagnosed
paroxysmal atrial fibrillation or patent foramen ovale
(PFO) in this study population.
The link between cardioembolic stroke and
migraine with visual aura suggests that visual aura
symptoms may be related to distal emboli, and there
may be shared pathogenesis for migraine with visual
aura and cardiac emboli. To determine possible cause
for stroke, we used a computerized algorithm based
on the National Survey of Stroke,17 along with expert
physician review. Cardioembolism was considered if
the medical records revealed evidence of valvular heart
disease, atrial fibrillation or flutter, cardiac or arterial
procedure, acute or recent (within 4 weeks) intracar-
diac thrombus, or bacterial endocarditis. Data on
PFO or cryptogenic stroke subtype are not available
in ARIC. Data from the Women’s Health Study
(WHS) showed that most of the ischemic strokes in
patients withmigraine with aura were due to “infarct of
unknown mechanism”14; however, no conclusive re-
sults regarding stroke subtypes from WHS can be ob-
tained due to lack of statistical significance.While PFO
is a common condition, found on autopsy in 25% of
the population, approximately 40%–50% of individ-
uals with cryptogenic stroke have PFO on transesopha-
geal echocardiography.19 Increased prevalence of PFO
Table 2 Stroke occurrence and distribution of stroke subtypes in the Atherosclerosis Risk in Communities study (1993–2012)
Migraine with visual aura
(n 5 463), n (%)
Migraine without visual aura
(n 5 1,159), n (%)
Nonmigraine headache
(n 5 1,083), n (%)
No headache
(n 5 10,053), n (%)
Incidence rate (per
1,000 person-years) Incidence
Incidence rate (per
1,000 person-years) Incidence
Incidence rate (per
1,000 person-years) Incidence
Incidence rate (per
1,000 person-years) Incidence
Stroke 4.1 38 (8.2) 2.07 48 (4.1) 2.44 53 (5) 3.02 607 (6)
Stroke subtypes
Thrombotic 2.05 19 (4) 1.38 32 (2.7) 1.2 26 (2.4) 1.42 286 (2.8)
Cardioembolic 1.29 12 (2.6) 0.39 9 (0.7) 0.5 11 (1) 0.93 187 (1.8)
Lacunar 0.65 6 (1.3) 0.3 7 (0.6) 0.69 15 (1.4) 0.66 134 (1.3)
Table 1 Demographic characteristics and selected stroke risk factors in the
Atherosclerosis Risk in Communities study
Migraine with
visual aura
(n 5 463), n (%)
Migraine without
visual aura
(n 5 1,159), n (%)
Nonmigraine
headache
(n 5 1,083), n (%)
No headache
(n 5 10,053),
n (%)
Mean age, y 59 58 59 60
Female 376 (82) 874 (75) 672 (62) 5,184 (51)
Caucasian 371 (81) 997 (86) 911 (84.7) 7,504 (74.7)
African American 85 (18.5) 160 (13.8) 165 (15) 2,513 (25)
Other 2 (0.5) 1 (0.2) 4 (0.31) 31 (0.3)
Obesity (BMI >30) 169 (37) 329 (28) 305 (28) 3,413 (34)
Hypertension 221 (48) 426 (37) 394 (36) 4,053 (40)
Diabetes mellitus 47 (10) 87 (7.5) 83 (7.7) 1,014 (10)
Smoking 242 (53) 616 (53) 634 (59) 6,004 (60)
Hyperlipidemia
(LDL >100 mg/dL)
356 (77) 890 (77) 805 (74) 7,846 (78)
NSAID use 136 (30) 295 (25) 215 (20) 1,569 (16)
Physical activitya 257 (55) 714 (62) 648 (60) 6,233 (62)
Abbreviations: BMI5 body mass index; LDL5 low-density lipoprotein; NSAID5 nonsteroidal
anti-inflammatory drugs.
aGreater than 3 h/wk and for at least 1 month duration.
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in patients with migraine with aura has been well-
documented,20–22 and PFO has been shown to be as
a source of microembolism.23 However, PFO cannot
be considered as a definite cause for cardioembolic
stroke. Taken together, it is possible that migraine with
visual aura may promote vasospasm, activate platelet
aggregation,24–26 and increased concentration of pro-
coagulant factors.27–30 Directly or indirectly in the set-
ting of PFO, these vasoactive substances could gain
access to coronary artery as well as cerebral vasculature,
Table 3 Hazard ratios (95% confidence intervals [CI]) for the association of migraine with visual aura
compared to migraine without visual aura and risk of verified ischemic stroke (all types)
Unadjusted
hazard ratio 95% CI p
Adjusted
hazard ratioa 95% CI p
Migraine 0.9 0.7–1.1 0.25 1.1 0.9–1.5 0.36
Migraine with visual aura 1.4 1.0–2.0 0.052 1.67 1.1–2.4 0.014
Migraine without visual aura 1.47 1.0–2.0 0.01 1.2 0.8–1.7 0.359
aAdjusted for age, sex, race, body mass index, hypertension, diabetes, smoking, alcohol intake, nonsteroidal anti-
inflammatory drugs use, physical activity, and low-density lipoprotein levels.
Figure The association of thrombotic, cardioembolic, and lacunar subtype of stroke and migraine with/without visual aura (limited data
available)
A) Kaplan-Meier survival distribution for stroke in patients with migraine with aura and migraine without aura. (B) Kaplan-Meier survival distribution for large
artery atherosclerosis in patients with migraine with aura and migraine without aura. (C) Kaplan-Meier survival distribution for cardioembolic stroke in pa-
tients with migraine with aura and migraine without aura. (D) Kaplan-Meier survival distribution for lacunar stroke in patients with migraine with aura and
migraine without aura.
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where they induce visual aura symptoms, and subse-
quently may result in brain ischemic injury if larger
emboli are formed.
Our data suggest that migraine without visual aura
is not an isolated risk factor for stroke, in our sample,
when compared to healthy controls without any
headache history; any association identified can be ex-
plained by the traditional stroke risk factors (it is also
possible that the number of participants with
migraine without visual aura is too low, and the study
is underpowered to detect an association with stroke).
Fewer studies have reported migraine without aura as
an isolated risk factor for stroke,10,11 and the majority
of epidemiologic evidence supports no link between
ischemic stroke and migraine without aura.12–15
Our findings are consistent with several studies
that reported a link between migraine with aura and
increased risk of ischemic stroke. In our study popu-
lation, the mean age of participants was 59 years, and
the age range varied from 49 to 73 at the time of start
of prospective follow-up; an average duration of
migraine history in this subset of population was 19
years. This suggests that on average, the onset of
migraine in this study population started between
ages 30 and 54. The results of our study are limited
to this specific age group. It is possible that in younger
individuals (35–45), regardless of aura symptoms,
migraine is associated with ischemic stroke, as pre-
viously reported.
Interestingly, calcitonin gene-related peptide
(CGRP), one of the most important neuropeptides
involved in an acute migraine attack, is also found
to have a potent effect on coronary vasodilation.31
Although speculative, it is possible that fluctuation
of CGRP level throughout a migraine attack may
trigger coronary blood flow/velocity changes, and
therefore increase risk of atrial fibrillation in patients
with recurrent migraine. While it may be true in
general that migraineurs, regardless of their status
of visual aura, have elevated CGRP levels, we do
not know if there is differential expression of CGRP
levels in older migraineurs with or without visual
aura. Furthermore, it is possible that there are other
important neuropeptides/proinflammatory cyto-
kines involved, which may only affect those with
visual aura and not those without visual aura. As
individuals younger than 45 were excluded from
the study population, these findings cannot be gen-
eralized to younger populations.
There are several limitations of our study. First,
the stroke subtype algorithm requires the presence
of a possible cardioembolic source for classification
of cardioembolic stroke; however, this may not neces-
sarily mean cardioembolism is the etiology of the
ischemic stroke. In addition, artery-to-artery embolic
stroke (e.g., dislodged carotid plaque) is classified in
ARIC as atherothrombotic. Lacunar stroke in ARIC
is based on imaging features, regardless of the pres-
ence or absence of a lacunar stroke syndrome, and
therefore may miss lacunar strokes with negative
scans. In addition, some lacunar strokes may be cardi-
oembolic in etiology. Even though current classifica-
tion does not allow for clear distinction between these
subtypes, we do not expect misclassification to differ
on the basis of migraine with visual aura history. Sec-
ond, the migraine classification used in ARIC is based
on questionnaires, administered in late midlife, and
subject to recall bias. Migraine with aura symptoms
only included visual aura and may have inadvertently
excluded migraine with sensory, motor (hemiplegic
migraine), or brainstem aura due to the 1995 design
of the headache questionnaire. We do not expect this
to significantly alter our findings as between 82% and
90% of patients who have migraine with aura experi-
ence visual aura.32 In addition, the modified ICHD
III-beta criteria we used were more stringent and it is
possible that we may have classified a few migraineurs
who presented with bilateral headache or lasted less
than 1 year as nonmigraine headache group. How-
ever, we do not expect this to be biased in respect to
association with stroke, and thus it would not neces-
sarily change results. Finally, unlike stroke diagnosis,
headache diagnosis in the ARIC cohort has not been
adjudicated by a headache specialist.
The strength of this study includes its prospective
design, longer follow-up period, large population
cohort, and availability of covariates that may con-
found the study results. Our ascertainment of
migraine and ischemic stroke is closely aligned with
the current diagnostic criteria.
Despite the above limitations, this study demon-
strates that there is significant increased risk of cardi-
oembolic stroke, as defined in this study, in this
sample of individuals with migraine with visual aura.
In addition, we found that increased risk of ischemic
stroke is not associated with migraine without visual
aura, although this could be due to limited power to
detect an association. Further prospective clinical stud-
ies focusing on cardioembolic and cryptogenic stroke in
migraine with visual aura are needed to better under-
stand the pathophysiology linking these 2 entities.
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